On April 21, two linked studies were published (Miyara et al. and Changeux et al.), neither of which has been formally peer-reviewed. Both are on the website Qeios which allows authors to upload studies without peer-review in order to expedite publication and access to findings.
The first study (Miyara et al.) is a small study which examined smoking rates among patients with COVID-19 in a single hospital in Paris. It compared smoking rates in patients with smoking rates in the French population as a whole. The principal finding was that among patients with COVID-19 (including out-patients and in-patients, but excluding those most ill in intensive care), current smoking rates were low. There are significant limitations in the study design which suggest it is likely to under-estimate levels of current smoking. Further, as the study was based in a hospital where it appears that a significant proportion of the cases were health care workers, it can say little about the risk of acquiring infection in the community. Nevertheless, it used its tentative findings to make strong claims\(^1\) that smoking protects against infection with SARS-CoV-2 and recommend that nicotine may therefore provide a route to protecting against disease.

These tentative findings are then expanded on in a second study (Changeux et al.) which proposes a new hypothesis of how the virus might enter the body and cause neurological disease, arguing that nicotine could reduce the risk and provide a new treatment option.

While the evidence base is changing rapidly, it is important to note that the findings of these studies are inconsistent with the broader emerging literature on the links between smoking and COVID-19 and more widely accepted hypotheses on how infection occurs.

Nevertheless, the press coverage of these studies has unfortunately failed to identify the study weaknesses and the existence of evidence to the contrary, leading to potentially dangerous misinformation that smoking may be protective and prompting people to panic buy nicotine.

Further, while no source of funding for his paper is detailed, we note that Changeux, the lead author of the second paper, has long-standing historical links with the tobacco industry: Between 1995 and 1998 he received grants amounting to a total of USD $220,000 from the Council for Tobacco Research;\(^2\) in the late 1990s he became a collaborator and advisor for Targacept, a pharmaceutical subsidiary of the tobacco company RJ Reynolds;\(^3\) and in 2006/2007 he supervised and published studies funded by Philip Morris International.\(^4\)

---

\(^1\) For example, the conclusions states that the study "strongly suggests that daily smokers have a very much lower probability of developing symptomatic or severe SARS-CoV-2 infection".

\(^2\) The Council for Tobacco Research was formerly known as the Tobacco Industry Research Committee, which was established in 1953 by the major tobacco companies to help produce research that would help them obscure the links between smoking and serious illness. See [https://www.tobaccotactics.org/index.php/Tobacco.Industry.Research.Committee](https://www.tobaccotactics.org/index.php/Tobacco.Industry.Research.Committee)

Changeux’s involvement with the Council has been amply discussed in an investigation by Le Monde, available here: [https://www.lemonde.fr/sciences/article/2012/05/31/guerre-du-tabac-la-bataille-de-la-nicotine_1710837_1650684.html](https://www.lemonde.fr/sciences/article/2012/05/31/guerre-du-tabac-la-bataille-de-la-nicotine_1710837_1650684.html)

Changeux’s letter in which he approaches the Council for funding is available here: [https://www.industrydocuments.ucsf.edu/tobacco/docs/#id=vzkw0085](https://www.industrydocuments.ucsf.edu/tobacco/docs/#id=vzkw0085)

\(^3\) For internal documents by Targacept identifying Changeux as a key advisor see [https://www.industrydocuments.ucsf.edu/tobacco/docs/#id=mhkx0190](https://www.industrydocuments.ucsf.edu/tobacco/docs/#id=mhkx0190) and [https://www.industrydocuments.ucsf.edu/tobacco/docs/#id=jtfy0221](https://www.industrydocuments.ucsf.edu/tobacco/docs/#id=jtfy0221)

\(^4\) Changeux’s ties with Philip Morris International have been discussed in Eker F, Béguinot E, Martinet Y, Ingérence de l’industrie du tabac dans les politiques de santé publiques. Comité National Contre Le Tabagisme, Paris, 2014, pp. 89, 280. Philip Morris-funded studies co-authored by Changeux include [https://www.pnas.org/content/104/51/20570](https://www.pnas.org/content/104/51/20570) and [https://www.pnas.org/content/103/45/16965](https://www.pnas.org/content/103/45/16965)